글로버메뉴 바로가기 본문 바로가기 하단메뉴 바로가기

논문검색은 역시 페이퍼서치

> 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회) > Allergy Asthma & Respiratory Disease > 1권 3호

아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가

ORIGINAL ARTICLE : Effect of infosheet for topical tacrolimus 0.1% and its efficacy and compliance in the treatment of atopic dermatitis

한지수 ( Ji Su Han ) , 이우진 ( Woo Jin Lee ) , 고주연 ( Joo Yeon Ko ) , 김정수 ( Joung Soo Kim ) , 김상석 ( Sang Seok Kim ) , 서수홍 ( Soo Hong Seo ) , 유박린 ( Bark Lynn Lew ) , 이가영 ( Ga Young Lee ) , 이주희 ( Ju Hee Lee ) , 박창욱 ( Chang Ook Park ) , 장상재 ( Sang Jai Jang ) , 박현수

- 발행기관 : 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회)

- 발행년도 : 2013

- 간행물 : Allergy Asthma & Respiratory Disease, 1권 3호

- 페이지 : pp.221-226 ( 총 6 페이지 )


학술발표대회집, 워크숍 자료집 중 1,2 페이지 논문은 ‘요약’만 제공되는 경우가 있으니,

구매 전에 간행물명, 페이지 수 확인 부탁 드립니다.

4,000
논문제목
초록(외국어)
Purpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance. (Allergy Asthma Respir Dis 2013;1:221-226)

논문정보
  • - 주제 : 의약학분야 > 소아과학
  • - 발행기관 : 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회)
  • - 간행물 : Allergy Asthma & Respiratory Disease, 1권 3호
  • - 발행년도 : 2013
  • - 페이지 : pp.221-226 ( 총 6 페이지 )
  • - UCI(KEPA) : I410-ECN-0102-2015-500-000272526
저널정보
  • - 주제 : 의약학분야 > 소아과학
  • - 성격 : 학술지
  • - 간기 : 격월
  • - 국내 등재 : KCI 등재
  • - 해외 등재 : -
  • - ISSN : 2288-0402
  • - 수록범위 : 2013–2015
  • - 수록 논문수 : 208